Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms

Bickel, 1988, Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans, Journal of Pharmacology & Experimental Therapeutics, 247, 47 Fudala, 2003, Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone, New England Journal of Medicine, 349, 949, 10.1056/NEJMoa022164 Harris, 2004, Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: Lack of dose proportionality, Clinical Pharmacokinetics, 43, 329, 10.2165/00003088-200443050-00005 Johnson, 2000, A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence, New England Journal of Medicine, 343, 1290, 10.1056/NEJM200011023431802 Johnson, 1992, A controlled trial of buprenorphine treatment for opioid dependence, JAMA, 267, 2750, 10.1001/jama.267.20.2750 Kosten, 1993, Buprenorphine versus methadone maintenance for opioid dependence, Journal of Nervous & Mental Disease, 181, 358, 10.1097/00005053-199306000-00004 Kuhlman, 1996, Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine, Journal of Analytical Toxicology, 20, 369, 10.1093/jat/20.6.369 Kuhlman, 1998, Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine, Addiction, 93, 549, 10.1046/j.1360-0443.1998.93454910.x Ling, 1998, Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial, Addiction, 93, 475, 10.1046/j.1360-0443.1998.9344753.x Mattick, 2002, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Database of Systematic Reviews, CD002207 McGettigan, 2000, Basic principles of clinical pharmacology relevant to pharmacoepidemiology studies Mello, 1980, Buprenorphine suppresses heroin use by heroin addicts, Science, 207, 657, 10.1126/science.7352279 Mendelson, 1997, Bioavailability of sublingual buprenorphine, Journal of Clinical Pharmacology, 37, 31, 10.1177/009127009703700106 Mendelson, 1996, Buprenorphine pharmacokinetics: Bioavailability of an 8 mg sublingual tablet formulation, 112 Moody, 2002, A liquid chromatographic–electrospray ionization–tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies, Analytical Biochemistry, 306, 31, 10.1006/abio.2002.5673 Nath, 1999, Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tables and liquid formulations, Journal of Clinical Pharmacology, 39, 619, 10.1177/00912709922008236 O'Connor, 1998, A pilot study of three dose schedules for thrice-weekly administration of buprenorphine Schottenfeld, 2000, Thrice-weekly versus daily buprenorphine maintenance, Biological Psychiatry, 47, 1072, 10.1016/S0006-3223(99)00270-X Schottenfeld, 1997, Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse, Archives of General Psychiatry, 54, 713, 10.1001/archpsyc.1997.01830200041006 Schuh, 1999, Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet, Drug and Alcohol Dependence, 56, 55, 10.1016/S0376-8716(99)00012-5 Strain, 2004, Relative bioavailability of different buprenorphine formulations under chronic dosing conditions, Drug and Alcohol Dependence, 74, 37, 10.1016/j.drugalcdep.2003.11.008 Strain, 1994, Comparison of buprenorphine and methadone in the treatment of opioid dependence, American Journal of Psychiatry, 151, 1025, 10.1176/ajp.151.7.1025